News and Announcements
Sementis Ltd – CEO Interview
- Published November 13, 2014 11:53AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Sementis is a biotech company developing vaccines for peanut allergy and chikungunya (like dengue fever, a mosquito-borne disease spreading throughout the world). There is an early stage pipeline for vaccines for Ebola, Q Fever, Melanoma (skin Cancer) and prostate Cancer.
The vaccines use Sementis’ “SCV” backbone technology. This is a vaccinia virus (which is also a smallpox vaccine) genetically altered to prevent replication in human cells thus ensuring safety and, through further manipulation, able to increase its immune stimulating properties. The genes for antigens from diseases are added to the SCV, which, with vaccination, elicits an immune response to the disease state in the human body.
Sementis’ Non-executive Chairman, Maurice O’Shannassy spent 25 years in the financial services industry in Australia, the United Kingdom and Asia. His most recent role was that of CEO of BlackRock Investment Management in Australia. Prior to that he was the CEO and CIO of the Asian operations of BlackRock’s antecedents, Merrill Lynch Investment Management and Mercury Asset Management.
Please listen to Sementis’ Non-executive Chairman, Mr. Maurice O’Shannassy.
Executive Interviews
The A$20.4 Million Inertia Trap: How Kepa Software Is Unlocking Value in Enterprise Capital Allocation
A government agency renewed the same maintenance decision nine years running, because auditing the original choice was deemed too expensive. When the portfolio was finally tested, A$20.4 million of low value spend was identified in a single year. Kepa Software’s capital governance platform was built to expose and eliminate precisely these boardroom blind spots. For […]
Forget the share price. SpaceX just published a map of the next five years.
Most coverage of SpaceX’s result focused on a 9.1% share price fall. That is noise. The signal is in the transcript: compute, power, bandwidth and demand over the next five years.
The prefab company that deliberately leaves part of the house unbuilt
BuiltQuik prefabricates the floor and roof structure and stops there. Co-founder Ryan Mullaney argues the omission is the product. Prefabricated housing usually means a factory. A large central facility, identical modules, limited room to move on design, and a logistics problem getting the finished box to site. BuiltQuik builds the opposite, and the design decision […]
Backed By Leading Investment Groups and Family Offices
